Bristol Myers Squibb (BMS; NYSE: BMY) announced this week that its Phase III study evaluating the combination of anti-PD-1 drug Opdivo (nivolumab) and anti-CTLA-4 biologic Yervoy (ipilimumab) as a first-line treatment for advanced hepatocellular carcinoma (HCC) has yielded promising top-line results.
According to data from a pre-specified interim analysis, the trial successfully met its primary endpoint, demonstrating improved overall survival (OS) compared to monotherapy with tyrosine kinase inhibitors (TKIs) such as sorafenib or lenvatinib. The safety profile of the experimental treatment remained consistent with findings from earlier studies, reinforcing its potential as a viable option for patients with no prior systemic therapy.- Flcube.com
